Obesity is a major and growing problem around the world, but especially in the U.S. Researchers have long looked for medications that can help people lose weight, mostly with disappointing and, in some cases, dangerous results.
FILE- A closeup of a beam scale is seen in New York on April 3, 2018. Tirzepatide, a drug from Eli Lilly and Co. approved to treat type 2 diabetes under the brand name Mounjaro, helped people with the disease who were overweight or had obesity lose up to 16% of their body weight, or more than 34 pounds, over nearly 17 months, the company said on Thursday, April 27, 2023.
Obesity is linked to scores of health problems that can lead to disability or even death, including high blood pressure, diabetes, heart disease, stroke, cancer and joint problems. Now, a new drug made by Eli Lilly and Co., called tirzepatide, is poised to become the most potent obesity drug on the market, promising users losses of more than 30 to 50 pounds over time.
Tirzepatide targets GLP-1, but also affects a second hormone, called GIP, which developers say contributes to its increased effectiveness. Mounjaro was approved to treat diabetes in May 2022. The latest study of tirzepatide studied the drug in more than 900 patients with diabetes who were overweight or had obesity over nearly 17 months. It showed weight loss of up to 16% of body weight, more than 34 pounds, when using the highest dose of the drug. Patients who received placebo, or dummy injections, lost about 3% of their body weight, or 7 pounds.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Powerful new obesity drug poised to upend weight loss careAs a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment. Tirzepatide, an Eli Lilly and Co. drug approved to treat type 2 diabetes under the brand name Mounjaro, helped people with the disease who were overweight or had obesity lose up to 16% of their body weight, or more than 34 pounds, over nearly 17 months, the company said on Thursday. The late-stage study of the drug for weight loss adds to earlier evidence that similar participants without diabetes lost up to 22% of their body weight over that period with weekly injections of the drug.
Read more »
Powerful new obesity drug poised to upend weight loss careThe late-stage study of the drug for weight loss adds to earlier evidence that similar participants without diabetes lost up to 22% of their body weight over that period with weekly injections of the drug.
Read more »
Powerful new obesity drug poised to upend weight loss careAs a growing number of overweight Americans clamor for Ozempic and Wegovy -- drugs touted by celebrities and on TikTok to pare pounds -- an even more powerful obesity medicine is poised to upend treatment.
Read more »
Powerful new obesity drug poised to upend weight loss careBased on the new results, company officials said they will finalize an application to the FDA for fast-track approval to sell it for chronic weight management.
Read more »
Bariatric Surgery Cuts Risk for Obesity-Related Cancers: StudyFor years evidence has pointed to multiple health benefits associated with bariatricsurgery, including improvements in diabetes, sleep apnea, and blood pressure. Now researchers are adding cutting cancer risk by more than half to the list.
Read more »
Ultra-High Energy Absorption Breakthrough: Chinese Researchers Unveil Game-Changing Nanolattice MetamaterialsMechanical Metamaterials Fabricated With Ultra-high Energy Absorption Capacity Researchers have created a nanolattice metamaterial with ultra-high energy absorption capacity using ion track technology, achieving a record low beam diameter of 34 nm and demonstrating excellent energy absorption and c
Read more »